Skip to main content

Table 1 Univariable and multivariable analyses for OS data

From: Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel

 

mOS

HR univariable

(95% CI)

p-value

HR multivariable (95% CI)

p-value

Entire cohort (95% CI)

10.9 (7.8–14.0)

     

Age ≤ 65

6.9

     

Age > 65

13.2

0.57 (0.32–1.02)

0.062

0.50 (0.26–0.96)

0.039

Locally advanced

17.1

     

Metastasized

9.4

1.62 (0.85–3.09)

0.114

1.45 (0.73–2.94)

0.287

ECOG PS 0

14.5

     

ECOG PS 1–2

9.4

1.37 (0.76–2.48)

0.288

1.16 (0.63–2.17)

0.633

Ca19–9 ≤ mediana

11.0

     

Ca19–9 > median

10.4

1.12 (0.61–2.07)

0.715

  

Ca19–9 < 59xULN

11.3

    

Ca19–9 ≥ 59xULN

6.8

1.59 (0.84–3.01)

0.187

  

Albumin ≤37 g/L

8.3

     

Albumin > 37 g/L

14.8

0.53 (0.30–0.95)

0.032

0.48 (0.26–0.90)

0.023

TPK grade 0

6.8

     

TPK grade 1–4

14.7

0.29 (0.16–0.55)

0.001

0.54 (0.27–1.06)

0.073

Normal bilirubinb

11.3

     

Elevated bilirubin

10.1

1.59 (0.56–4.51)

0.421

  

Dose reduction

10.9

     

Full dose

6.2

1.77 (0.90–3.51)

0.119

1.03 (0.50–2.13)

0.942

No 2nd line

8.2

     

2nd line

12.0

0.80 (0.45–1.42)

0.429

  

BM-tox grade 0–1

7.0

     

BM-tox grade 2–4

14.5

0.46 (0.25–0.84)

0.017

  

BM-tox grade 0–2

8.9

     

BM-tox grade 3–4

not reachedc

0.41 (0.20–0.87)

0.012

0.58 (0.26–1.27)

0.172

No leucocytosisd

11.9

     

Leucocytosis

8.2

1.41 (0.78–2.57)

0.272

  
  1. Median OS in months. Abbreviations: HR Hazard ratio, CI Confidence interval, PS Performance status, TPK Platelet count, BM Bone marrow, LPK White blood cell count, ULN Upper limit of normal. aMedian CA19–9 was 567kU/l, bS-bil < 26 μmole/L at treatment start, c Due to censored cases (61%),d < 8.8 × 109/L at treatment start. Statistical significance at the 0.05 level marked in bold text.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us